Sfoglia per AUTORE
MUSU L
Collezione AOU San Luigi di Orbassano
Items : 2
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. in Journal of neurology / J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26.
2018
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Prosperini L; Annovazzi P; Boffa L; Buscarinu MC; Gallo A; Matta M; Moiola L; Musu L; Perini P; Avolio C; Barcella V; Bianco A; Farina D; Ferraro E; Pontecorvo S; Granella F; Grimaldi LME; Laroni A; Lus G; Patti F; Pucci E; Pasca M; Sarchielli P;
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology / Neurol Sci. 2014 Feb;35(2):307-16. doi: 10.1007/s10072-013-1616-1. Epub 2013 Dec 29.
2014
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Bertolotto A; Capobianco M; Amato MP; Capello E; Capra R; Centonze D; Di Ioia M; Gallo A; Grimaldi L; Imberti L; Lugaresi A; Mancinelli C; Marrosu MG; Moiola L; Montanari E; Romano S; Musu L; Paolicelli D; Patti F; Pozzilli C; Rossi S; Salvetti M; Tedeschi G; Tola MR; Trojano M; Zaffaroni M; Malucchi S;